Thomson Medical Group Ltd. (A50) AI Stock Analysis

• Market Cap: S$1.61B
• Dividend Yield: N/A
• Average Volume (3M): 2.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: 12.39%
• EPS Growth: -400.00%
• Country: SG
• Employees: 699
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 26,441,066,000
• 10 Day Avg. Volume: 2,062,170
• 30 Day Avg. Volume: 2,143,033
• PEG Ratio: 0.05
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 2.88
• P/FCF Ratio: 33.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): S$557.67M

• Rating: 46 Neutral
• Price Target: S$0.06 ▲(5.00% Upside)

Overall score is held back primarily by weak financial performance (declining revenue, negative profitability, high leverage, and poor free cash flow trends). Technicals are a bright spot with price trading above major moving averages and positive MACD, but valuation is undermined by losses (negative P/E) and no dividend yield support.

Positive Factors

High gross margin

A 74.8% gross margin indicates strong pricing power and efficient service delivery in core medical services. High gross margins provide a structural buffer to absorb SG&A or reimbursement pressure, supporting long-term reinvestment in technology and patient services.

Leading Singapore market position

Scale and brand leadership in Singapore’s hospital and clinic network create durable competitive advantages: stable patient volumes, referral networks, and higher trust for maternity/fertility services. This structural position supports steady demand and pricing over months.

Insurance partnerships and service diversification

Partnerships with insurers plus diverse revenue streams (maternity, fertility, outpatient, screenings) deliver more predictable insured patient flows and reduce single-service dependency. This structural diversification aids utilization and medium-term revenue stability.

Negative Factors

High leverage

A debt-to-equity ratio of 2.38 signals elevated financial risk and limited balance sheet flexibility. High leverage increases interest expense sensitivity and constrains the company’s ability to fund capex or absorb demand shocks without refinancing or deleveraging over the coming quarters.

Negative net profitability

A negative net margin (-12.05%) shows the business is losing money after expenses and financing. Sustained losses erode equity, limit internal reinvestment and make it harder to execute growth or modernization plans unless operational efficiencies or pricing improvements are implemented.

Weak cash flow generation

Severely deteriorated free cash flow and low operating-cash-to-net-income ratio indicate poor cash conversion. This structural cash weakness hampers debt repayment, capital investments and strategic initiatives, raising refinancing and liquidity risks over the medium term.

Thomson Medical Group Ltd. Business Overview & Revenue Model

Company Description

Thomson Medical Group Ltd. (A50) is a leading healthcare provider in Singapore, specializing in a wide range of medical services including obstetrics, gynecology, pediatrics, and general healthcare. The company operates a network of hospitals and clinics, focusing on delivering high-quality medical care through advanced technology and a patient-centric approach. Thomson Medical Group also offers fertility services, health screenings, and a variety of wellness programs, making it a comprehensive healthcare provider in the region.

How the Company Makes Money

Thomson Medical Group generates revenue primarily through patient services, which include inpatient and outpatient care, consultations, and surgeries across its facilities. The company earns significant income from its maternity services, fertility treatments, and specialized healthcare offerings. Additionally, revenue is bolstered by health screening packages and wellness programs. The group has established partnerships with various health insurance companies, enabling a steady flow of patients covered under insurance plans. Furthermore, Thomson Medical Group may also benefit from government healthcare initiatives and grants aimed at enhancing healthcare delivery in Singapore.

Thomson Medical Group Ltd. Financial Statement Overview

Summary

Weak fundamentals: revenue declined (-9.17%), net margin is negative (-12.05%), and leverage is high (debt-to-equity 2.38). Cash flow is also pressured with sharply negative free cash flow growth (-636.22%) and low operating cash flow to net income (0.22), despite a strong gross margin (74.83%).

Income Statement

Thomson Medical Group Ltd. has experienced a decline in revenue growth, with a negative growth rate of -9.17% in the latest year. The gross profit margin remains strong at 74.83%, but the net profit margin has turned negative at -12.05%, indicating profitability challenges. The EBIT and EBITDA margins have also decreased significantly, reflecting operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has increased to 2.38, indicating high leverage and potential financial risk. Return on equity is negative at -10.10%, highlighting challenges in generating returns for shareholders. The equity ratio stands at 26.38%, suggesting a moderate level of equity financing.

Cash Flow

Free cash flow growth has significantly declined by -636.22%, and the operating cash flow to net income ratio is low at 0.22, indicating cash flow challenges. The free cash flow to net income ratio is 0.56, showing some ability to convert net income into cash flow, but overall cash flow performance is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	455.53M	394.66M	351.15M	355.77M	333.71M	240.40M
Gross Profit	220.71M	295.33M	275.39M	296.39M	278.38M	116.02M
EBITDA	41.73M	57.72M	109.08M	106.78M	110.72M	59.54M
Net Income	-47.58M	-47.58M	14.16M	36.55M	53.76M	14.24M
Balance Sheet
Total Assets	1.78B	1.78B	1.81B	1.45B	1.36B	1.29B
Cash, Cash Equivalents and Short-Term Investments	124.21M	124.21M	167.28M	286.59M	161.59M	114.51M
Total Debt	1.12B	1.12B	1.12B	762.79M	642.86M	631.08M
Total Liabilities	1.24B	1.24B	1.23B	872.34M	756.60M	719.74M
Stockholders Equity	470.89M	470.89M	499.72M	499.44M	531.68M	489.84M
Cash Flow
Free Cash Flow	37.86M	33.79M	52.99M	75.81M	64.68M	23.96M
Operating Cash Flow	60.45M	60.45M	83.35M	88.59M	92.80M	61.25M
Investing Cash Flow	-27.16M	-27.16M	-489.99M	-13.39M	-29.44M	-37.57M
Financing Cash Flow	-71.19M	-71.19M	281.32M	54.22M	-23.48M	-58.82M

Thomson Medical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:A50, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.06 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:A50.

Thomson Medical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
A50	46 Neutral	S$1.61B	-33.89	-9.99%	―	12.39%	-400.00%

Thomson Medical Group Ltd. Corporate Events

Thomson Medical Group Names Tong Kooi Ong as Chairman to Steer Next Growth Phase

Thomson Medical Group has appointed entrepreneur and veteran corporate leader Tong Kooi Ong as Chairman of the Board with effect from 1 February 2026, replacing Ng Ser Miang, who steps down after nearly a decade in the role. The board transition comes as the group moves into its next phase of growth, with management highlighting Tong’s track record in large-scale, capital-intensive developments and his extensive regional business networks as critical assets for advancing Thomson Medical’s leadership in the healthcare sector, including the ambitious Johor Bay project in the Johor–Singapore Special Economic Zone.

The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.

Thomson Medical Reshapes Board Leadership and Committees

Thomson Medical Group Limited has announced changes to its board leadership, appointing Mr Tong Kooi Ong as Chairman and Independent Non-Executive Director with effect from 1 February 2026, succeeding Mr Ng Ser Miang, who will resign on 31 January 2026. The company is also reconstituting its board committees from 1 February 2026, with updated memberships for the Audit and Risk Committee and the Nominating and Remuneration Committee, signalling a refreshed governance structure that may influence strategic oversight and risk management for shareholders and other stakeholders.

The most recent analyst rating on (SG:A50) stock is a Hold with a S$0.06 price target. To see the full list of analyst forecasts on Thomson Medical Group Ltd. stock, see the SG:A50 Stock Forecast page.

Thomson Medical Group’s AGM Highlights Financial Performance and Growth Plans

Thomson Medical Group Limited held its Annual General Meeting (AGM) on October 31, 2025, at Voco Orchard Singapore. The meeting included presentations by the Group Chief Financial Officer and the Group Chief Executive Officer, who discussed the company’s financial performance for FY2025 and provided updates on business operations and growth plans. The AGM concluded with the voting on resolutions, emphasizing the company’s commitment to transparency and strategic growth.

Thomson Medical Group Releases Q3 2025 Financial Report

Thomson Medical Group Ltd. has released its unaudited interim financial report for the financial quarter ending on 30 September 2025. This report provides stakeholders with insights into the company’s financial performance during this period, although specific details of the financial outcomes are not disclosed in the release.

Thomson Medical Group Reports Revenue Growth in Vietnam Amid Economic Challenges

Thomson Medical Group Limited announced a significant increase in revenue for its Vietnamese operations, Far East Medical Vietnam Limited, from $50 million in FY2024 to $98 million in FY2025. Despite this growth, net profit slightly decreased due to higher operating costs and macroeconomic factors, including tariffs in Vietnam. The company recorded an impairment loss on goodwill of $75 million for the acquisition of FEMVN, reflecting challenges in the economic environment. The announcement highlights the demand for private healthcare in Vietnam and the strong reputation of FV Hospital, although the financial performance did not fully meet expectations.

Thomson Medical Group Adopts Market Capitalisation for Materiality Thresholds

Thomson Medical Group Ltd. has announced a change in its method for calculating materiality thresholds due to its negative net tangible asset position as of June 2025. The company will now use market capitalisation as a reference point, which has been approved by the Singapore Exchange Securities Trading Limited, to better reflect the business’s scale and valuation for the financial year ending June 2026.